<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35852606</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Cellular and molecular life sciences : CMLS</Title><ISOAbbreviation>Cell Mol Life Sci</ISOAbbreviation></Journal><ArticleTitle>Increased surface P2X4 receptors by mutant SOD1 proteins contribute to ALS pathogenesis in SOD1-G93A mice.</ArticleTitle><Pagination><StartPage>431</StartPage><MedlinePgn>431</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-022-04461-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal motoneuron (MN) disease characterized by protein misfolding and aggregation leading to cellular degeneration. So far neither biomarker, nor effective treatment has been found. ATP signaling and P2X4 receptors (P2X4) are upregulated in various neurodegenerative diseases. Here we show that several ALS-related misfolded proteins including mutants of SOD1 or TDP-43 lead to a significant increase in surface P2X4 receptor density and function in vitro. In addition, we demonstrate in the spinal the cord of SOD1-G93A (SOD1) mice that misfolded SOD1-G93A proteins directly interact with endocytic adaptor protein-2 (AP2); thus, acting as negative competitors for the interaction between AP2 and P2X4, impairing constitutive P2X4 endocytosis. The higher P2X4 surface density was particularly observed in peripheral macrophages of SOD1 mice before the onset and during the progression of ALS symptoms positioning P2X4 as a potential early biomarker for ALS. P2X4 expression was also upregulated in spinal microglia of SOD1 mice during ALS and affect microglial inflammatory responses. Importantly, we report using double transgenic SOD1 mice expressing internalization-defective P2X4mCherryIN knock-in gene or invalidated for the P2X4 gene that P2X4 is instrumental for motor symptoms, ALS progression and survival. This study highlights the role of P2X4 in the pathophysiology of ALS and thus its potential for the development of biomarkers and treatments. We also decipher the molecular mechanism by which misfolded proteins related to ALS impact P2X4 trafficking at early pathological stage in cells expressing-P2X4.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertin</LastName><ForeName>El&#xe9;onore</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, CNRS, IMN, UMR 5293, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, CNRS, IMN, UMR 5293, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayoux</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, CNRS, EPHE, INCIA, UMR 5287, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172, LilNCog, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Alzheimer &amp; Tauopathies", LabEx DISTALZ, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carracedo</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, CNRS, IMN, UMR 5293, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernagut</LastName><ForeName>Pierre-Olivier</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Univ. Poitiers, INSERM, LNEC, UMR-S 1084, 86073, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch-Nolte</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172, LilNCog, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Alzheimer &amp; Tauopathies", LabEx DISTALZ, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bertrand</LastName><ForeName>Sandrine S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, CNRS, EPHE, INCIA, UMR 5287, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bou&#xe9;-Grabot</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2187-9037</Identifier><AffiliationInfo><Affiliation>Univ. Bordeaux, CNRS, IMN, UMR 5293, 33000, Bordeaux, France. eric.boue-grabot@u-bordeaux.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ANR-20-CE17-001</GrantID><Agency>ANR</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cell Mol Life Sci</MedlineTA><NlmUniqueID>9705402</NlmUniqueID><ISSNLinking>1420-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058848">Receptors, Purinergic P2X4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058848" MajorTopicYN="Y">Receptors, Purinergic P2X4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Macrophage</Keyword><Keyword MajorTopicYN="N">P2X</Keyword><Keyword MajorTopicYN="N">Purinergic signaling</Keyword><Keyword MajorTopicYN="N">Receptor trafficking</Keyword><Keyword MajorTopicYN="N">Spinal cord</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35852606</ArticleId><ArticleId IdType="pmc">PMC9296432</ArticleId><ArticleId IdType="doi">10.1007/s00018-022-04461-5</ArticleId><ArticleId IdType="pii">10.1007/s00018-022-04461-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Cashman NR. Prion-like activity of Cu/Zn superoxide dismutase: implications for amyotrophic lateral sclerosis. Prion. 2014;8:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7030911</ArticleId><ArticleId IdType="pubmed">24394345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e35050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320864</ArticleId><ArticleId IdType="pubmed">22493728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Zaidi S, Iltis C, Ribon M, Berriat F, Schiaffino L, Jolly A, de la Grange P, Mallat M, Bohl D, et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat Neurosci. 2020;23:1339&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">33077946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Lobsiger CS, Boillee S. New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:764&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">31306211</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, Parisi C, Amadio S. Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology. 2016;104:180&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">26514402</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Amadio S, Cavaliere F, D'Ambrosi N, Vacca F, Bernardi G. Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neurol Disord. 2003;2:403&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">14683468</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, Carri MT, D'Ambrosi N. ALS: focus on purinergic signalling. Pharmacol Ther. 2011;132:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">21704075</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7:575&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">18591979</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology. 2016;104:4&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26056033</ArticleId></ArticleIdList></Reference><Reference><Citation>Erb L, Woods LT, Khalafalla MG, Weisman GA. Purinergic signaling in Alzheimer's disease. Brain Res Bull. 2019;151:25&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">30472151</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth A, Antal Z, Bereczki D, Sperlagh B. Purinergic signalling in Parkinson's disease: a multi-target system to combat neurodegeneration. Neurochem Res. 2019;44:2413&#x2013;2422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776560</ArticleId><ArticleId IdType="pubmed">31054067</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Purinergic Signalling and Neurological Diseases: An Update. CNS Neurol Disord Drug Targets. 2017;16:257&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha RA. Caffeine, adenosine receptors, memory and Alzheimer disease. Med Clin (Barc) 2008;131:790&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">19094882</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci. 2009;29:14741&#x2013;14751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665997</ArticleId><ArticleId IdType="pubmed">19940169</ArticleId></ArticleIdList></Reference><Reference><Citation>Morato X, Lujan R, Lopez-Cano M, Gandia J, Stagljar I, Watanabe M, Cunha RA, Fernandez-Duenas V, Ciruela F. The Parkinson's disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo. Sci Rep. 2017;7:9452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573386</ArticleId><ArticleId IdType="pubmed">28842709</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, Huin V, Hansen JN, Kozlov S, Danis C, et al. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain. 2019;142:3636&#x2013;3654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6821333</ArticleId><ArticleId IdType="pubmed">31599329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pougnet JT, Toulme E, Martinez A, Choquet D, Hosy E, Boue-Grabot E. ATP P2X receptors downregulate AMPA receptor trafficking and postsynaptic efficacy in hippocampal neurons. Neuron. 2014;83:417&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">25033184</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh BS, North RA. Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron. 2012;76:51&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064466</ArticleId><ArticleId IdType="pubmed">23040806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pougnet JT, Compans B, Martinez A, Choquet D, Hosy E, Boue-Grabot E. P2X-mediated AMPA receptor internalization and synaptic depression is controlled by two CaMKII phosphorylation sites on GluA1 in hippocampal neurons. Sci Rep. 2016;6:31836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5022001</ArticleId><ArticleId IdType="pubmed">27624155</ArticleId></ArticleIdList></Reference><Reference><Citation>Boue-Grabot E, Pankratov Y. Modulation of central synapses by astrocyte-released ATP and postsynaptic P2X receptors. Neural Plast. 2017;2017:9454275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563405</ArticleId><ArticleId IdType="pubmed">28845311</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Krugel U. P2Y receptors: focus on structural, pharmacological and functional aspects in the brain. Curr Med Chem. 2007;14:2429&#x2013;2455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17979698</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaliere F, Florenzano F, Amadio S, Fusco FR, Viscomi MT, D'Ambrosi N, Vacca F, Sancesario G, Bernardi G, Molinari M, Volonte C. Up-regulation of P2X2, P2X4 receptor and ischemic cell death: prevention by P2 antagonists. Neuroscience. 2003;120:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849743</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke H, Illes P. Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmacol Ther. 2006;109:297&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102837</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanovas A, Hernandez S, Tarabal O, Rossello J, Esquerda JE. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis. J Comp Neurol. 2008;506:75&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">17990272</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Montilli C, Finocchi P, Amadio S. Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events. Febs J. 2009;276:354&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">19076216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabala A, Vazquez-Villoldo N, Rissiek B, Gejo J, Martin A, Palomino A, Perez-Samartin A, Pulagam KR, Lukowiak M, Capetillo-Zarate E, et al. P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis. EMBO Mol Med. 2018;10:e8743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079537</ArticleId><ArticleId IdType="pubmed">29973381</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho K, Martin E, Ces A, Sarrazin N, Lagouge-Roussey P, Nous C, Boucherit L, Youssef I, Prigent A, Faivre E, et al. P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy. Prog Neurobiol. 2021;206:102139.</Citation><ArticleIdList><ArticleId IdType="pubmed">34391810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmann L, Hirbec H, Rassendren F. P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain. EMBO J. 2010;29(14):2290&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910276</ArticleId><ArticleId IdType="pubmed">20562826</ArticleId></ArticleIdList></Reference><Reference><Citation>Bou&#xe9;-Grabot E, Pankratov Y. Modulation of central synapses by astrocyte-released ATP and postsynaptic P2X receptors. Neural Plast. 2017;2017:9454275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563405</ArticleId><ArticleId IdType="pubmed">28845311</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2009;32:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">19008000</ArticleId></ArticleIdList></Reference><Reference><Citation>Montilla A, Mata GP, Matute C, Domercq M. Contribution of P2X4 receptors to CNS function and pathophysiology. Int J Mol Sci. 2020;21:5562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7432758</ArticleId><ArticleId IdType="pubmed">32756482</ArticleId></ArticleIdList></Reference><Reference><Citation>Duveau A, Bertin E, Boue-Grabot E. Implication of Neuronal Versus Microglial P2X4 Receptors in Central Nervous System Disorders. Neurosci Bull. 2020;36:1327&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674530</ArticleId><ArticleId IdType="pubmed">32889635</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Zhong XZ, Zou Y, Murrell-Lagnado R, Zhu MX, Dong XP. Calcium release through P2X4 activates calmodulin to promote endolysosomal membrane fusion. J Cell Biol. 2015;209:879&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477861</ArticleId><ArticleId IdType="pubmed">26101220</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P, Zou Y, Zhong XZ, Cao Q, Zhao K, Zhu MX, Murrell-Lagnado R, Dong XP. P2X4 forms functional ATP-activated cation channels on lysosomal membranes regulated by luminal pH. J Biol Chem. 2014;289:17658&#x2013;17667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067200</ArticleId><ArticleId IdType="pubmed">24817123</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulme E, Garcia A, Samways D, Egan TM, Carson MJ, Khakh BS. P2X4 receptors in activated C8&#x2013;B4 cells of cerebellar microglial origin. J Gen Physiol. 2010;135:333&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847917</ArticleId><ArticleId IdType="pubmed">20231374</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson LE, Murrell-Lagnado RD. The trafficking and targeting of P2X receptors. Front Cell Neurosci. 2013;7:233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837535</ArticleId><ArticleId IdType="pubmed">24319412</ArticleId></ArticleIdList></Reference><Reference><Citation>Beggs S, Trang T, Salter MW. P2X4R+ microglia drive neuropathic pain. Nat Neurosci. 2012;15:1068&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023423</ArticleId><ArticleId IdType="pubmed">22837036</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma R, Chai Y, Troncoso J, Gu J, Xing H, Stojilkovic SS, Mattson MP, Haughey NJ. Amyloid-beta induces a caspase-mediated cleavage of P2X4 to promote purinotoxicity. Neuromol Med. 2009;11:63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735730</ArticleId><ArticleId IdType="pubmed">19562525</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries M, Van Damme P, Robberecht W, Van Den Bosch L. Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2007;25:8&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17045808</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrosi N, Finocchi P, Apolloni S, Cozzolino M, Ferri A, Padovano V, Pietrini G, Carri MT, Volonte C. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J Immunol. 2009;183:4648&#x2013;4656.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424:778&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin E, Deluc T, Pilch KS, Martinez A, Pougnet JT, Doudnikoff E, Allain AE, Bergmann P, Russeau M, Toulme E, et al. Increased surface P2X4 receptor regulates anxiety and memory in P2X4 internalization-defective knock-in mice. Mol Psychiatry. 2021;26:629&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">31911635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez S, Casanovas A, Piedrafita L, Tarabal O, Esquerda JE. Neurotoxic species of misfolded SOD1G93A recognized by antibodies against the P2X4 subunit of the ATP receptor accumulate in damaged neurons of transgenic animal models of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2010;69:176&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20084016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim JA, Chaumont S, Jo J, Ulmann L, Young MT, Cho K, Buell G, North RA, Rassendren F. Altered hippocampal synaptic potentiation in P2X4 knock-out mice. J Neurosci. 2006;26:9006&#x2013;9009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675341</ArticleId><ArticleId IdType="pubmed">16943557</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience. 2002;114:1005&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo YH, Donier E, Martinez A, Garret M, Toulme E, Boue-Grabot E. Cross-talk between P2X4 and gamma-aminobutyric acid, type A receptors determines synaptic efficacy at a central synapse. J Biol Chem. 2011;286:19993&#x2013;20004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103373</ArticleId><ArticleId IdType="pubmed">21482824</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulme E, Soto F, Garret M, Boue-Grabot E. Functional properties of internalization-deficient P2X4 receptors reveal a novel mechanism of ligand-gated channel facilitation by ivermectin. Mol Pharmacol. 2006;69:576&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin E, Martinez A, Boue-Grabot E. P2X electrophysiology and surface trafficking in Xenopus oocytes. Methods Mol Biol. 2020;2041:243&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">31646494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010;35:1488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152216</ArticleId><ArticleId IdType="pubmed">20110936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobanovic LK, Royle SJ, Murrell-Lagnado RD. P2X receptor trafficking in neurons is subunit specific. J Neurosci. 2002;22:4814&#x2013;4824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757758</ArticleId><ArticleId IdType="pubmed">12077178</ArticleId></ArticleIdList></Reference><Reference><Citation>Royle SJ, Bobanovic LK, Murrell-Lagnado RD. Identification of a non-canonical tyrosine-based endocytic motif in an ionotropic receptor. J Biol Chem. 2002;277:35378&#x2013;35385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105201</ArticleId></ArticleIdList></Reference><Reference><Citation>Royle SJ, Qureshi OS, Bobanovic LK, Evans PR, Owen DJ, Murrell-Lagnado RD. Non-canonical YXXGPhi endocytic motifs: recognition by AP2 and preferential utilization in P2X4 receptors. J Cell Sci. 2005;118:3073&#x2013;3080.</Citation><ArticleIdList><ArticleId IdType="pubmed">15985462</ArticleId></ArticleIdList></Reference><Reference><Citation>Adencreutz M, Hau J. Studies of neonatal and juvenile neuromuscular locomotor development of C57BL/6/Bkl, 129SvEv/Bkl and F1 hybrid mice in swim tests. In Vivo. 2004;18:733&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">15646814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann P, Garcia de Paco E, Rissiek B, Menzel S, Dubberke G, Hua J, Rassendren F, Ulmann L, Koch-Nolte F. Generation and characterization of specific monoclonal antibodies and nanobodies directed against the ATP-gated channel P2X4. Front Cell Neurosci. 2019;13:498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861843</ArticleId><ArticleId IdType="pubmed">31798414</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Bernstein AM, Wong A, Lu XH, Khoja S, Yang XW, Davies DL, Micevych P, Sofroniew MV, Khakh BS. P2X4 receptor reporter mice: sparse brain expression and feeding-related presynaptic facilitation in the arcuate nucleus. J Neurosci. 2016;36:8902&#x2013;8920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995303</ArticleId><ArticleId IdType="pubmed">27559172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bataveljic D, Stamenkovic S, Bacic G, Andjus PR. Imaging cellular markers of neuroinflammation in the brain of the rat model of amyotrophic lateral sclerosis. Acta Physiol Hung. 2011;98:27&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21388928</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis KE, Rasmussen AL, Bennett W, King A, West AK, Chung RS, Chuah MI. Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase. J Neuroinflammation. 2014;11:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994340</ArticleId><ArticleId IdType="pubmed">24655927</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Turner MR. Untangling neuroinflammation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(12):1303&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">31296587</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, Leigh PN, Banati RB. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Moller T. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. NeuroReport. 2005;16:527&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">15812300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson JA. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics. 2010;7:471&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967019</ArticleId><ArticleId IdType="pubmed">20880509</ArticleId></ArticleIdList></Reference><Reference><Citation>Layhadi JA, Fountain SJ. P2X4 receptor-dependent Ca(2+) influx in model human monocytes and macrophages. Int J Mol Sci. 2017;18:2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5713231</ArticleId><ArticleId IdType="pubmed">29077063</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015;77:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664586</ArticleId><ArticleId IdType="pubmed">26663933</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Iwamoto S, Yoshinaga R, Tozaki-Saitoh H, Nishiyama A, Mak TW, Tamura T, Tsuda M, Inoue K. Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain. Nat Commun. 2014;5:3771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024744</ArticleId><ArticleId IdType="pubmed">24818655</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberberg SD, Li M, Swartz KJ. Ivermectin Interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. Neuron. 2007;54:263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442247</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes L. Rab5 regulates internalisation of P2X4 receptors and potentiation by ivermectin. Purinergic Signal. 2012;9:113&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568434</ArticleId><ArticleId IdType="pubmed">23086000</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues RJ, Tome AR, Cunha RA. ATP as a multi-target danger signal in the brain. Front Neurosci. 2015;9:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412015</ArticleId><ArticleId IdType="pubmed">25972780</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Montilli C, Volonte C, D'Ambrosi N. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:4102&#x2013;4116.</Citation><ArticleIdList><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Parisi C, Matteucci A, Potenza RL, Armida M, Popoli P, D'Ambrosi N, Volonte C. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis Model Mech. 2014;7:1101&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadet S, Allard J, Brisson L, Lopez-Charcas O, Lemoine R, Heraud A, Lerondel S, Guibon R, Fromont G, Le Pape A, et al. P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition. Oncogene. 2022;41:2920&#x2013;2931.</Citation><ArticleIdList><ArticleId IdType="pubmed">35411034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, Buell GN, Reeve AJ, Chessell IP, Rassendren F. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci. 2008;28:11263&#x2013;11268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671487</ArticleId><ArticleId IdType="pubmed">18971468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Morillas A, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci. 2021;22:1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7915979</ArticleId><ArticleId IdType="pubmed">33561958</ArticleId></ArticleIdList></Reference><Reference><Citation>Layhadi JA, Turner J, Crossman D, Fountain SJ. ATP evokes Ca(2+) responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages. J Immunol. 2018;200:1159&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784824</ArticleId><ArticleId IdType="pubmed">29255078</ArticleId></ArticleIdList></Reference><Reference><Citation>Csoka B, Nemeth ZH, Szabo I, Davies DL, Varga ZV, Paloczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, et al. Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI Insight. 2018;3:e99431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997389</ArticleId><ArticleId IdType="pubmed">29875325</ArticleId></ArticleIdList></Reference><Reference><Citation>Suurvali J, Boudinot P, Kanellopoulos J, Ruutel Boudinot S. P2X4: A fast and sensitive purinergic receptor. Biomed J. 2017;40:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138603</ArticleId><ArticleId IdType="pubmed">29179879</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyke JM, Smit-Oistad IM, Macrander C, Krakora D, Meyer MG, Suzuki M. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS) Exp Neurol. 2016;277:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4762214</ArticleId><ArticleId IdType="pubmed">26775178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammana S, Fagone P, Cavalli E, Basile MS, Petralia MC, Nicoletti F, Bramanti P, Mazzon E. The role of macrophages in neuroinflammatory and neurodegenerative pathways of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis: pathogenetic cellular effectors and potential therapeutic targets. Int J Mol Sci. 2018;19:831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5877692</ArticleId><ArticleId IdType="pubmed">29533975</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber DJ, Hickey WF, Harris BT. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825214</ArticleId><ArticleId IdType="pubmed">20109233</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A, Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1:60&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560453</ArticleId><ArticleId IdType="pubmed">22787561</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi OS, Paramasivam A, Yu JC, Murrell-Lagnado RD. Regulation of P2X4 receptors by lysosomal targeting, glycan protection and exocytosis. J Cell Sci. 2007;120:3838&#x2013;3849.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940064</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063&#x2013;3087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, Muller K, Khalaji S, Bliederhauser C, Ruf WP, Grozdanov V, Thiemann M, Fundel-Clemes K, Freischmidt A, Holzmann K, et al (2016) Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol 132: 391&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>